ACCC has long highlighted the racial and ethnic disparities that exist in oncology and hematology care delivery to advocate for true health equity for all patients with cancer. Through various programs, ACCC helps teach members of the multidisciplinary cancer care team how they can help patients overcome barriers and disparities in various treatment settings.
Prostate cancer is one of the most common cancers in this country; the American Cancer Society (ACS) estimates that 1 male in every 8 will be diagnosed with prostate cancer at some point in their lifetime. The ACS also estimates that there will be 248,530 new cases and 34,130 deaths from prostate cancer in 2021—an increase of 30% and 2.4%, respectively—compared to 2020. This increased risk is at least partially due to the stay-at-home orders brought on by the COVID-19 pandemic, which led many Americans to avoid trips to doctors’ offices for annual visits and cancer screenings. Continued growth in healthcare disparities—also aggravated by COVID-19— has added to the disproportionate access of marginalized groups to necessary cancer screenings and quality cancer care.
ZERO —The End of Prostate Cancer published a report in January 2021 that highlights the disparities in care the Black community continues to face in the context of COVID-19: “The incidence of prostate cancer is almost 80% higher in non-Hispanic Black men than in non-Hispanic white men, and the death rate for Black men with prostate cancer is more than double that of men in every other population.” Many factors contribute to these disparities, including social determinants of health (e.g., low health literacy, low economic status, and lack of transportation), patients being underinsured or uninsured, and language barriers between patients and members of their care team. As risk and mortality rates are predicted increase once again in 2021, the fight against prostate cancer is critical.
Designated as Prostate Cancer Awareness Month, September is a time to fight for health equity for all patients at risk for and diagnosed with prostate cancer. ACCC has long highlighted the racial and ethnic disparities that exist in oncology and hematology care delivery to advocate for true health equity for all patients with cancer. Through various programs, ACCC helps teach members of the multidisciplinary cancer care team how they can help patients overcome barriers and disparities in various treatment settings.
Getting Involved
Currently, ACCC is leading a critical effort to better understand the barriers patients with advanced prostate cancer face in shared decision-making—a proven strategy to better manage patients at each stage of their treatment. Shared decision-making offers patients the opportunity to engage with their healthcare providers and be active participants in their care, as this helps clinicians better tailor individual treatments to meet patients’ needs and preferences.
As part of this effort, ACCC will conduct a web-based, national survey of its members to inform the development of resources and tools for health systems, cancer programs and practices, and communities at regional and local levels to reduce racial disparities in prostate cancer care. This effort is a key element of the ACCC project, “Comprehensive Care of Patients with Advanced Prostate Cancer Through Shared Decision-Making.”
On Monday, October 4, ACCC will host a virtual multidisciplinary summit on treating advanced prostate cancer in the community setting, which will be informed by the national survey. Experts will lead attendees through an exploration of practical solutions for overcoming the challenges associated with treating advanced prostate cancer. Summit hosts will also lead a discussion of the strategies that can be used to improve care delivery and better inform decision-making for patients. The objectives of the summit are to highlight:
Attendees will help identify actionable items that can guide community cancer care
teams in expanding access to high-quality advanced prostate cancer care. Those interested in participating in the summit can
.
Other ongoing ACCC prostate cancer projects include:
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
